This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Neovii Biotech
ClinicalTrials.gov Identifier:
NCT01295710
First received: February 9, 2011
Last updated: May 13, 2016
Last verified: May 2016
February 9, 2011
May 13, 2016
June 2011
September 2016   (Final data collection date for primary outcome measure)
First occurrence of moderate or severe chronic GVHD according to NIH criteria or death from any cause after allogeneic stem cell transplantation [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT01295710 on ClinicalTrials.gov Archive Site
  • Acute GVHD [ Time Frame: 12 months ]
    Incidence of and time to
  • Chronic GVHD [ Time Frame: 12 months ]
    Incidence of and time to mild to severe, moderate to severe, and severe
  • Overall survival [ Time Frame: 12 months ]
    Transplant related mortality
  • Relapse [ Time Frame: 12 months ]
    Incidence of and time of
  • Systemic immunosuppressive medication for treatment of chronic GVHD [ Time Frame: 12 months ]
    Incidence of and time to start of
  • Incidence of and time to acute GVHD [ Time Frame: 12 months ]
  • Incidence of and time to mild to severe, moderate to severe, and severe chronic GVHD [ Time Frame: 12 months ]
  • Survival [ Time Frame: 12 months ]
  • Incidence of and time of relapse [ Time Frame: 12 months ]
  • Incidence of and time to start of systemic immunosuppressive medication for treatment of chronic GVHD [ Time Frame: 12 months ]
Not Provided
Not Provided
 
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.

This study is randomized, prospective, double-blind, placebo-controlled, phase 3 study evaluating the prevention of moderate to severe chronic GVHD in patients undergoing bone marrow or peripheral blood stem cell transplantation from matched, unrelated donors for acute leukemia and myelodysplastic syndrome during the first year after transplant.

Patients meeting all the inclusion and none of the exclusion criteria will be randomized (1:1). All patients will receive premedication and study drug 3 days prior to transplantation.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • GVHD
  • Adult Acute Myeloid Leukemia
  • Adult Acute Lymphoid Leukemia
  • Myelodysplastic Syndrome
  • Biological: US-ATG-F
    20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
    Other Name: Anti-human-T-lymphocyte Immune Globulin, Rabbit
  • Biological: Placebo
    250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
  • Active Comparator: US-ATG-F
    20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
    Intervention: Biological: US-ATG-F
  • Placebo Comparator: Placebo
    250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
    Intervention: Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
260
December 2016
September 2016   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome)
  • Patients with an unrelated HLA-A,-B, -C and -DRBI matched donor
  • Patients with a Karnofsky Performance Score ≥ 70%

Key Exclusion Criteria:

  • Clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and CNS)
  • Bacterial, viral, or fungal infections
  • Known positive for Hepatitis B surfaces antigen, or Hepatitis C antibody, or who have been tested positive for HIV
  • Patients with any concurrent malignancy. Cancer treated with curative intent < 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ
  • Known contraindications to the administration of rabbit immunoglobulin antibodies
  • Hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   United States
 
 
NCT01295710
IV-ATG-SCT-01
Yes
Not Provided
Not Provided
Neovii Biotech
Neovii Biotech
Not Provided
Study Director: Anne Kuan Neovii Biotech
Neovii Biotech
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP